Energy Products Inc

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of APYX Medical Corporation (APYX) Investors and Encourages Investors to Contact the Firm Before August 5, 2022

Retrieved on: 
Friday, June 17, 2022
Legal, Professional Services, FDA, LLP, Advanced Energy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lists of schools in England, Court, Company, Douglas v. U.S. District Court ex rel Talk America, Kirby, NASDAQ, District court, Energy Products Inc, News, Food, Coagulation, Medical device, Private investigator

Investors have until August 5, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until August 5, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Apyx Medical is an energy technology company develops products in the cosmetic and surgical markets.
  • On March 14, 2022, Apyx Medical disclosed that the U.S. Food and Drug Administration (FDA) would be posting a Medical Device Safety Communication (MDSC) related to the Companys Advanced Energy Products.
  • Kirby McInerney LLP is a New York-based plaintiffs law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

APYX MEDICAL CORPORATION (NASDAQ: APYX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apyx Medical Corporation (NASDAQ: APYX)

Retrieved on: 
Wednesday, June 15, 2022
Helium, Securities Exchange Act of 1934, FDA, NEW, Company, Advanced Energy, Regulation of tobacco by the U.S. Food and Drug Administration, Lists of schools in England, Court, The Legal 500, Lists of action films, Labour government, Advertising, Investment, NASDAQ, District court, Energy Products Inc, News, Food, Coagulation, GLOBE, Tobacco, Pharmaceutical industry, Online gambling, Security (finance)

NEW YORK, June 15, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Apyx Medical Corporation (“Apyx” or the “Company”) (NASDAQ: APYX) between May 12, 2021 and March 11, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Middle District of Florida and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • If so, please visit Apyx Medical Corporation Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Middle District of Florida and alleges violations of the Securities Exchange Act of 1934.
  • Apyx claims to be an advanced energy technology company with products in the cosmetic and surgical markets.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Apyx Medical Corporation Shareholder Update: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Apyx Medical Corporation (APYX)

Retrieved on: 
Wednesday, June 15, 2022
Steps, Complaint, Securities Exchange Act of 1934, FDA, Advanced Energy, Person, Company, NASDAQ, Energy Products Inc, News, Coagulation, SAN, GLOBE, Pharmaceutical industry

Apyx claims to be an advanced energy technology company with products in the cosmetic and surgical markets.

Key Points: 
  • Apyx claims to be an advanced energy technology company with products in the cosmetic and surgical markets.
  • If you would like more information about Apyx Medical Corporation's misconduct, click here .
  • On March 14, 2022, Apyx disclosed that the FDA would be posting a Medical Device Safety Communication (MDSC) related to the Companys Advanced Energy Products.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

APYX MEDICAL CORPORATION CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Middle District of Florida against Apyx Medical Corporation

Retrieved on: 
Tuesday, June 14, 2022
Haldenstein, Energy Products Inc, District court, Company, Advanced Energy, Food, Court, News, Telephone, Coagulation, FDA, GLOBE, Defendant, NASDAQ, Lists of schools in England, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Person, Life insurance, Pharmaceutical industry, Risk management, Practice of law

All investors who purchased the shares of Apyx Medical Corporation and incurred losses are advised to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774.

Key Points: 
  • All investors who purchased the shares of Apyx Medical Corporation and incurred losses are advised to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774.
  • You may obtain additional information concerning the action or join the case on our website, www.whafh.com.
  • If you have incurred losses in Apyx Medical Corporation, you may, no later than August 5, 2022, request that the Court appoint you lead plaintiff of the proposed class.
  • Please contact Wolf Haldenstein to learn more about your rights as an investor in Apyx Medical Corporation.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Verrica, Apyx, and Waste Management and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, June 14, 2022
Waste management, New Drug Application, DOJ, Energy Products Inc, CMO, Company, Mergers and acquisitions, LLC, Advanced Energy, Food, News, Endpoint security, Failure, Office of Inspector General, U.S. Department of Health and Human Services, Coagulation, Waste Management (corporation), FDA, GFL Environmental, GLOBE, Defendant, U.S. Department of Justice Office of Legislative Affairs, SMR, Molluscum contagiosum, Prospectus, NYSE, Acquisition, NASDAQ, Negotiation, Tripura Merger Agreement, Lists of schools in England, NDA, P.C, Disclosure, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, Animal, Risk management, Audit, Bank, Note

In November 2021, Verrica resubmitted the NDA for VP-102, claiming [t]he resubmission addresses the successful resolution of inspection deficiencies at the manufacturing facility.

Key Points: 
  • In November 2021, Verrica resubmitted the NDA for VP-102, claiming [t]he resubmission addresses the successful resolution of inspection deficiencies at the manufacturing facility.
  • In the Notes prospectus, Waste Management represented that the Merger would close by the first quarter of 2020.
  • For more information on the Waste Management class action go to: https://bespc.com/cases/WM
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apyx Medical Corporation - APYX

Retrieved on: 
Tuesday, June 14, 2022
Energy Products Inc, Company, Advanced Energy, Food, News, Coagulation, FDA, GLOBE, NASDAQ, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LLP, Pomerantz, Private investigator

NEW YORK, June 13, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Apyx Medical Corporation (Apyx or the Company) (NASDAQ:APYX).

Key Points: 
  • NEW YORK, June 13, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Apyx Medical Corporation (Apyx or the Company) (NASDAQ:APYX).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Apyx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apyx Medical Corporation (APYX)

Retrieved on: 
Monday, June 13, 2022
Legal, Professional Services, Energy Products Inc, Time, Company, Advanced Energy, Food, Court, News, Telephone, Investment, FDA, Defendant, NASDAQ, Law, Lists of schools in England, Regulation of tobacco by the U.S. Food and Drug Administration, Suite, Security (finance), Pharmaceutical industry

Law Offices of Howard G. Smith reminds investors of the upcoming August 5, 2022 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Apyx Medical Corporation (Apyx or the Company) (NASDAQ: APYX ) securities between May 12, 2021 and March 11, 2022, inclusive (the Class Period).

Key Points: 
  • Law Offices of Howard G. Smith reminds investors of the upcoming August 5, 2022 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Apyx Medical Corporation (Apyx or the Company) (NASDAQ: APYX ) securities between May 12, 2021 and March 11, 2022, inclusive (the Class Period).
  • Investors suffering losses on their Apyx investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • On March 14, 2022, Apyx disclosed that the U.S. Food and Drug Administration (FDA) would be posting a Medical Device Safety Communication (MDSC) related to the Companys Advanced Energy Products.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

APYX Shareholder News: Robbins LLP Reminds Investors of Class Action Against Apyx Medical Corporation (APYX)

Retrieved on: 
Saturday, June 11, 2022
Legal, Professional Services, Steps, Energy Products Inc, Company, Securities Exchange Act of 1934, Advanced Energy, News, Coagulation, FDA, NASDAQ, Person, Complaint, Pharmaceutical industry

The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons or entities that purchased or otherwise acquired Apyx Medical Corporation (NASDAQ: APYX) securities between May 12, 2021 and March 11, 2022, for violations of the Securities Exchange Act of 1934.

Key Points: 
  • The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons or entities that purchased or otherwise acquired Apyx Medical Corporation (NASDAQ: APYX) securities between May 12, 2021 and March 11, 2022, for violations of the Securities Exchange Act of 1934.
  • Apyx claims to be an advanced energy technology company with products in the cosmetic and surgical markets.
  • If you would like more information about Apyx Medical Corporation's misconduct, click here .
  • On March 14, 2022, Apyx disclosed that the FDA would be posting a Medical Device Safety Communication (MDSC) related to the Companys Advanced Energy Products.

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of APYX Medical Corporation (APYX) Investors and Encourages Investors to Contact the Firm Before August 5, 2022

Retrieved on: 
Thursday, June 9, 2022
Energy Products Inc, District court, Company, Advanced Energy, Food, Court, Douglas v. U.S. District Court ex rel Talk America, News, FDA, GLOBE, NASDAQ, Lists of schools in England, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LLP, Kirby, Private investigator, Medical device

Investors have until August 5, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until August 5, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Apyx Medical is an energy technology company develops products in the cosmetic and surgical markets.
  • On March 14, 2022, Apyx Medical disclosed that the U.S. Food and Drug Administration (FDA) would be posting a Medical Device Safety Communication (MDSC) related to the Companys Advanced Energy Products.
  • Kirby McInerney LLP is a New York-based plaintiffs law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apyx Medical Corporation (APYX)

Retrieved on: 
Thursday, June 9, 2022
Legal, Professional Services, Energy Products Inc, Time, Company, Advanced Energy, Food, Court, News, Coagulation, FDA, Defendant, GPM, NASDAQ, Lists of schools in England, Regulation of tobacco by the U.S. Food and Drug Administration, Suite, Pharmaceutical industry

Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming August 5, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Apyx Medical Corporation (Apyx or the Company) (NASDAQ: APYX ) securities between May 12, 2021 and March 11, 2022, inclusive (the Class Period).

Key Points: 
  • Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming August 5, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Apyx Medical Corporation (Apyx or the Company) (NASDAQ: APYX ) securities between May 12, 2021 and March 11, 2022, inclusive (the Class Period).
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • If you purchased or otherwise acquired Apyx securities during the Class Period, you may move the Court no later than August 5, 2022 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.